Scholarlink

Background <p>Autosomal dominant polycystic kidney disease (ADPKD), the leading monogenic cause of kidney failure, exhibits heterogeneous clinical progression. This systematic review and meta-analysis synthesize and evaluate current evidence on blood and urine prognostic biomarkers in ADPKD, addressing gaps in understanding their role in predicting progression and guiding clinical trial selection and management.</p> Methods <p>We searched PubMed, Embase, and Cochrane up to April 2025 and screened articles in duplicate. We included longitudinal studies evaluating the blood and urine prognostic biomarkers in patients with ADPKD with at least 10 participants and 1 year of follow-up. We used the Quality in Prognosis Studies tool to assess risk of bias, random effects meta-analyses to pool effect estimates, and the GRADE approach to assess the certainty of evidence.</p> Results <p>We included 58 studies, with 33 urinary biomarkers and 29 serum/blood biomarkers identified. The most frequently studied biomarkers were urine osmolality, copeptin, proteinuria, Monocyte Chemoattractant Protein-1, and uric acid, whereas the most studied outcomes were estimated Glomerular Filtration Rate and Total Kidney Volume. The urinary biomarkers that showed the largest association with ADPKD were Monocyte Chemoattractant Protein-1, Kidney Injury Molecule-1, albumin, and Beta 2 microglobulin. Serum biomarkers associated with outcomes were primarily copeptin and Fibroblast Growth Factor-23, with β-Hydroxybutyrate and bicarbonate exhibiting lesser association.</p> Conclusion <p>In conclusion, this systematic review highlights the potential prognostic value of blood and urine biomarkers in ADPKD. It also verified the need for further validation of biomarker use in ADPKD.</p> Clinical trial number <p>Not applicable.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Serum and urine prognostic biomarkers for autosomal dominant polycystic kidney disease: a systematic review and meta-analysis

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年6月3日

查看全文
  • Jana Khawandi,
  • Vinamratha Rao,
  • Daniel G. Rayner,
  • Niveditha Girimaji,
  • Muayad Azzam,
  • Qais Hamarsha,
  • Hassan Kawtharany,
  • Ali Choaib,
  • Mustafa Qadir,
  • Alysha Khan,
  • Madhulika Sharma,
  • Pamela Tran,
  • Sorin Fedeles,
  • Wendy Ruyle,
  • Alan S. L. Yu,
  • Kenneth R. Hallows,
  • Ronald D. Perrone,
  • Farid Foroutan,
  • Reem A. Mustafa

摘要

Background

Autosomal dominant polycystic kidney disease (ADPKD), the leading monogenic cause of kidney failure, exhibits heterogeneous clinical progression. This systematic review and meta-analysis synthesize and evaluate current evidence on blood and urine prognostic biomarkers in ADPKD, addressing gaps in understanding their role in predicting progression and guiding clinical trial selection and management.

Methods

We searched PubMed, Embase, and Cochrane up to April 2025 and screened articles in duplicate. We included longitudinal studies evaluating the blood and urine prognostic biomarkers in patients with ADPKD with at least 10 participants and 1 year of follow-up. We used the Quality in Prognosis Studies tool to assess risk of bias, random effects meta-analyses to pool effect estimates, and the GRADE approach to assess the certainty of evidence.

Results

We included 58 studies, with 33 urinary biomarkers and 29 serum/blood biomarkers identified. The most frequently studied biomarkers were urine osmolality, copeptin, proteinuria, Monocyte Chemoattractant Protein-1, and uric acid, whereas the most studied outcomes were estimated Glomerular Filtration Rate and Total Kidney Volume. The urinary biomarkers that showed the largest association with ADPKD were Monocyte Chemoattractant Protein-1, Kidney Injury Molecule-1, albumin, and Beta 2 microglobulin. Serum biomarkers associated with outcomes were primarily copeptin and Fibroblast Growth Factor-23, with β-Hydroxybutyrate and bicarbonate exhibiting lesser association.

Conclusion

In conclusion, this systematic review highlights the potential prognostic value of blood and urine biomarkers in ADPKD. It also verified the need for further validation of biomarker use in ADPKD.

Clinical trial number

Not applicable.